New Data Presented on the Safety and Efficacy of Investigational AGN-190584 as a Potential Novel Treatment for Presbyopia, a Common and Progressive Eye Condition ...Middle East

NORTH CHICAGO, Ill., July 25, 2021 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, today announced new data, including the full results from the Phase 3 GEMINI 1 clinical study, evaluating the efficacy, safety and tolerability of investigational AGN-190584 (pilocarpine 1.25%)...

Hence then, the article about new data presented on the safety and efficacy of investigational agn 190584 as a potential novel treatment for presbyopia a common and progressive eye condition was published today ( Sunday 25/07/2021 - 07:45 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( New Data Presented on the Safety and Efficacy of Investigational AGN-190584 as a Potential Novel Treatment for Presbyopia, a Common and Progressive Eye Condition )

Also on site :

• Martha Stewart Says Reimagined Beauty Favorite, Originally Released 21 Years Ago, is ‘A Really Good Thing’
• Walmart’s $20 2-Pack of Solar Lanterns ‘Enhances Summer Nights’ With a ‘Magical Ambiance’ and Cottagecore Charm
• Webster native Haley Winn reflects on Olympic gold medal, Boston Fleet Rookie of the Year award after whirlwind year